Back to top
more

Valneva (VALN)

(Real Time Quote from BATS)

$7.56 USD

7.56
8,879

+0.11 (1.48%)

Updated May 1, 2024 02:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Strength Seen in Valneva SE Sponsored ADR (VALN): Can Its 15.8% Jump Turn into More Strength?

by Zacks Equity Research

Valneva SE Sponsored ADR (VALN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Valneva (VALN) Stock Down 53% in the Past Year: Here's Why

by Zacks Equity Research

The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.

Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why

by Zacks Equity Research

Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.

What Makes Valneva SE Sponsored ADR (VALN) a New Buy Stock

by Zacks Equity Research

Valneva SE Sponsored ADR (VALN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab

by Zacks Equity Research

Valneva (VALN) posts encouraging 12-month antibody persistence data for its single-shot chikungunya vaccine candidate, VLA1553. Shares rise.

Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data

by Zacks Equity Research

Persistence data from a mid-stage study showed that Valneva's (VALN) Lyme disease vaccine elicited antibody levels which remained above baseline six months after completing dose administration in children and adults.

Wall Street Analysts See a 65% Upside in Valneva SE Sponsored ADR (VALN): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Valneva SE Sponsored ADR (VALN) points to a 65.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

All You Need to Know About Valneva SE Sponsored ADR (VALN) Rating Upgrade to Buy

by Zacks Equity Research

Valneva SE Sponsored ADR (VALN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why

by Zacks Equity Research

Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.

Valneva SE Sponsored ADR (VALN) Stock Jumps 93.1%: Will It Continue to Soar?

by Zacks Equity Research

Valneva SE Sponsored ADR (VALN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Pfizer (PFE) to Buy 8.1% Stake in Lyme Disease Vaccine Partner

by Zacks Equity Research

Pfizer (PFE) is set to acquire 8.1% stake in Valneva's stock. Valneva will use the cash from this investment to support its phase III study for VLA15.

Valneva (VALN) Stock Declines 59% in 3 Months: Here's Why

by Zacks Equity Research

Though Valneva's (VALN) COVID-19 vaccine looks promising, the European Commission's intent to terminate the advance purchase agreement for the vaccine puts the future of the company's COVID-19 vaccine program into jeopardy.

Biotech Stock Roundup: BLUE Up on Regulatory Updates, RIGL's Pipeline News & More

by Zacks Equity Research

Regulatory and other updates from bluebird (BLUE) and Rigel (RIGL) are a few key highlights from the biotech sector during the past week.

Valneva (VALN) Down on its COVID-19 Vaccine Update in Europe

by Zacks Equity Research

Valneva (VALN) slides on a proposed remediation plan update after receiving the European Commission's notice of intent to terminate the Advance Purchase Agreement for its COVID-19 vaccine.

Dynavax (DVAX) Up as EMA Accepts Valneva's COVID-19 Vaccine MAA

by Zacks Equity Research

Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.

Valneva (VALN) Down as EU Considers Ending COVID-Vaccine Deal

by Zacks Equity Research

Per the agreement with the European Commission, Valneva (VALN) has 30 days from May 13, 2022 to win a marketing authorization in the EU for its COVID vaccine or offer an acceptable remediation plan.

Valneva (VALN) Completes Phase III Chikungunya Vaccine Study

by Zacks Equity Research

Valneva's (VALN) phase III study evaluating its chikungunya vaccine achieves all primary and secondary endpoints. The stock rises 9.2% following the announcement.

Will Dynavax's (DVAX) Growth Momentum Continue in 2022?

by Zacks Equity Research

Year-over-year revenue growth for HEPLISAV-B and CpG 1018 adjuvant is expected to drive Dynavax???s (DVAX) profitability in 2022.

Valneva (VALN) Up as COVID-19 Jab Neutralizes Omicron Variant

by Zacks Equity Research

Three doses of Valneva's (VALN) inactivated COVID-19 vaccine candidate, VLA2001, neutralizes the Omicron variant of SARS-CoV-2, per data from preliminary lab studies. Shares rally.

Biotech Stock Roundup: REGN Gets EC Nod for Cocktail, BIIB's Drug Approval & More

by Zacks Equity Research

Drug approvals for Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.

Valneva (VALN) Stock Rises on Deal With EU for COVID-19 Jab

by Zacks Equity Research

Valneva (VALN) enters into a supply agreement for its COVID vaccine candidate with the European Commission. The stock price surges following the news.

Dynavax (DVAX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Dynavax's (DVAX) topline comprising sales of hepatitis B vaccine Heplisav-B, vaccine adjuvant CpG 1018 and other revenues is expected to retain the growth momentum in Q3 results.

Biotech Stock Roundup: BIIB's Q3 Earnings, REGN's COVID-19 Cocktail Update & More

by Zacks Equity Research

Regulatory and pipeline updates from bigwigs like Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.

Valneva (VALN) Reports Positive Data From COVID Vaccine Study

by Zacks Equity Research

Valneva's (VALN) shares surge after its COVID vaccine demonstrates superiority over AstraZeneca's COVID vaccine in a phase III study.

Pfizer (PFE) Submits COVID-19 Vaccine Data on Children to FDA

by Zacks Equity Research

Pfizer (PFE) and BioNTech plan to seek emergency use authorization for Comirnaty in children 5 to less than 12 years of age.